scholarly journals Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report

2009 ◽  
Vol 24 (8) ◽  
pp. 532-537 ◽  
Author(s):  
K Gaddam ◽  
E Pimenta ◽  
S J Thomas ◽  
S S Cofield ◽  
S Oparil ◽  
...  
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Resistant Hypertension ◽  
Preliminary Report ◽  
Sleep Apnoea ◽  
Obstructive Sleep

Transoral Robotic Tongue Base Resection in Obstructive Sleep Apnoea-Hypopnoea Syndrome: A Preliminary Report

ORL ◽  
2010 ◽  
Vol 72 (1) ◽  
pp. 22-27 ◽  
Author(s):  
Claudio Vicini ◽  
Iacopo Dallan ◽  
Pietro Canzi ◽  
Sabrina Frassineti ◽  
Maria Grazia La Pietra ◽  
...  
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Preliminary Report ◽  
Sleep Apnoea ◽  
Tongue Base ◽  
Obstructive Sleep

scholarly journals Effectiveness of a 12-week physical exercise programme on blood pressure in adults with true resistant hypertension and high risk of obstructive sleep apnoea: a study protocol for a pre-post test non randomised clinical trial

2020 ◽  
Vol 7 (2) ◽  
pp. 112
Author(s):  
Suranga Dassanayake ◽  
Gerard Wilkins ◽  
Gisela Sole ◽  
Margot Skinner
Keyword(s):  
Physical Activity ◽  
Blood Pressure ◽  
High Risk ◽  
Obstructive Sleep Apnoea ◽  
Resistant Hypertension ◽  
Randomised Clinical Trial ◽  
Exercise Programme ◽  
Primary Outcome Measure ◽  
Sleep Apnoea ◽  
Obstructive Sleep

<p class="abstract"><strong>Background:</strong> Resistant hypertension, a special phenotype of hypertension, is associated with increased cardiovascular risk. Exercise and physical activity are recommended as non-pharmacological interventions to manage blood pressure in hypertension. Little is known about the effectiveness of exercise in resistant hypertension. A bidirectional relationship has been identified between resistant hypertension and obstructive sleep apnoea but the literature pertaining to the benefit of exercise for populations with both conditions, is minimal. This study aims to identify the effectiveness of exercise in reducing blood pressure in a cohort of adults with resistant hypertension and high risk of obstructive sleep apnoea.</p><p class="abstract"><strong>Methods:</strong> Dunedin based adults with resistant hypertension and high risk of obstructive sleep apnoea will be recruited from the community and health centres to participate in the study. Consenting volunteers (no. of fourteen) will participate in a 12-week exercise programme including aerobic and strength training. The primary outcome measure will be 24h ambulatory blood pressure while the secondary outcomes will be anthropometrics, activity parameters, sleep parameters, cardiac structure and function, and quality of life. The measurements at the end of the 12-week exercise programme will be compared with baseline to determine the effectiveness of exercise in reducing blood pressure in the cohort with resistant hypertension and risk of obstructive sleep apnoea.</p><p class="abstract"><strong>Conclusions: </strong>Exercise and physical activity are recommended to manage hypertension. Therefore, it is anticipated that the exercise programme will have a positive effect on the blood pressure of the participants. The findings have potential to change the direction of research in the area by filling the knowledge gaps.</p><p class="abstract"><strong>Trial Registration:</strong> The Ministry of Health, New Zealand (Ethics Ref: 18/CEN/257), Trial registry: ACTRN12618001881224p).</p>

scholarly journals Eplerenone as a treatment for resistant hypertension in pregnancy

2019 ◽  
pp. 1753495X1982596
Author(s):  
Jessica Gehlert ◽  
Adam Morton
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Resistant Hypertension ◽  
Mineralocorticoid Receptor ◽  
Sleep Apnoea ◽  
Primary Hyperaldosteronism ◽  
Mineralocorticoid Receptor Antagonists ◽  
Receptor Antagonists ◽  
Mineralocorticoid Receptor Antagonist ◽  
Obstructive Sleep ◽  
In Pregnancy

Mineralocorticoid receptor antagonists are highly effective in the management of resistant hypertension and primary hyperaldosteronism. Recent studies demonstrate that mineralocorticoid receptor antagonists significantly reduce blood pressure, severity of obstructive sleep apnoea and arterial stiffness in patients with resistant hypertension and moderate–severe obstructive sleep apnoea. Eplerenone is a selective mineralocorticoid receptor antagonist that does not act as an androgen receptor blocker, thus reducing the risk of fetal anti-androgenic effects. Rat and rabbit studies demonstrated that when exposed to 30 times the equivalent therapeutic human dose, 100 mg/day, there were no teratogenic or demasculinisation effects. To date, the use of eplerenone has been reported in six human pregnancies in women with Gitelman syndrome, primary hyperaldosteronism and cardiac failure, in which no teratogenic effects were seen. Described here is a case of resistant hypertension associated with obstructive sleep apnoea in pregnancy, treated with eplerenone. The potential role of using eplerenone in pregnancy as treatment for resistant hypertension is discussed. Trial registration: Not applicable.

scholarly journals ARTERIAL STIFFNESS AND OBSTRUCTIVE SLEEP APNOEA SEVERITY ASSOCIATION IN PATIENTS WITH RESISTANT HYPERTENSION

2019 ◽  
Vol 37 ◽  
pp. e109
Author(s):  
C. Roderjan ◽  
A. Cavalcanti ◽  
A. Cortez ◽  
B. Chedier ◽  
E. Muxfeldt ◽  
...  
Keyword(s):  
Arterial Stiffness ◽  
Obstructive Sleep Apnoea ◽  
Resistant Hypertension ◽  
Sleep Apnoea ◽  
Obstructive Sleep

Performance of NoSAS score versus Berlin questionnaire for screening obstructive sleep apnoea in patients with resistant hypertension

2018 ◽  
Vol 32 (7) ◽  
pp. 518-523 ◽  
Author(s):  
Sara Q. C. Giampá ◽  
Rodrigo P. Pedrosa ◽  
Carolina C. Gonzaga ◽  
Adriana Bertolami ◽  
Celso Amodeo ◽  
...  
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Resistant Hypertension ◽  
Sleep Apnoea ◽  
Berlin Questionnaire ◽  
Obstructive Sleep
Sign in / Sign up

Export Citation Format

Share Document